About ILiAD Biotechnologies, LLC

ILiAD is a clinical-stage biotechnology company developing the BPZE1 live attenuated vaccine to prevent and treat diseases caused by Bordetella pertussis, which leads to approximately 200,000 deaths and 16 million cases globally each year. The company's approach targets both the prevention of colonization and transmission of the bacteria, addressing a critical gap in current vaccination strategies.

```xml <problem> Pertussis, caused by the Bordetella pertussis bacteria, results in significant global morbidity and mortality, with approximately 200,000 deaths and 16 million cases annually. Current vaccination strategies primarily focus on disease prevention but do not effectively prevent bacterial colonization and transmission, leaving a critical gap in controlling the spread of pertussis. </problem> <solution> ILiAD Biotechnologies is developing BPZE1, a live attenuated vaccine, to prevent and treat diseases caused by Bordetella pertussis. The BPZE1 vaccine targets both the prevention of colonization and transmission of the bacteria, addressing a critical gap in current vaccination strategies. By preventing colonization, the vaccine aims to reduce the spread of the bacteria within communities, offering a more comprehensive approach to pertussis control. The live attenuated nature of the vaccine is intended to stimulate a robust and long-lasting immune response, providing enhanced protection against pertussis. </solution> <features> - Live attenuated vaccine designed to elicit a broad immune response. - Targets both prevention of disease and reduction of bacterial transmission. - Designed to prevent colonization of Bordetella pertussis. </features> <target_audience> The primary target audience includes infants, children, adolescents, and adults at risk of pertussis infection, as well as public health organizations seeking to control the spread of the disease. </target_audience> ```

What does ILiAD Biotechnologies, LLC do?

Where is ILiAD Biotechnologies, LLC located?

ILiAD Biotechnologies, LLC is based in Weston, United States.

When was ILiAD Biotechnologies, LLC founded?

ILiAD Biotechnologies, LLC was founded in 2012.

How much funding has ILiAD Biotechnologies, LLC raised?

ILiAD Biotechnologies, LLC has raised 42800000.

Location

Weston, United States

Founded

2012

Funding

42800000

Employees

24 employees

Major Investors

Knott Partners

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

ILiAD Biotechnologies, LLC

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

iliadbio.com 1K+

Crunchbase

Founded 2012 – Weston, United States

Funding

Estimated Funding

$20M+

Major Investors

Knott Partners

Team (20+)

No team information available.

Company Description

Problem

Pertussis, caused by the Bordetella pertussis bacteria, results in significant global morbidity and mortality, with approximately 200,000 deaths and 16 million cases annually. Current vaccination strategies primarily focus on disease prevention but do not effectively prevent bacterial colonization and transmission, leaving a critical gap in controlling the spread of pertussis.

Solution

ILiAD Biotechnologies is developing BPZE1, a live attenuated vaccine, to prevent and treat diseases caused by Bordetella pertussis. The BPZE1 vaccine targets both the prevention of colonization and transmission of the bacteria, addressing a critical gap in current vaccination strategies. By preventing colonization, the vaccine aims to reduce the spread of the bacteria within communities, offering a more comprehensive approach to pertussis control. The live attenuated nature of the vaccine is intended to stimulate a robust and long-lasting immune response, providing enhanced protection against pertussis.

Features

Live attenuated vaccine designed to elicit a broad immune response.

Targets both prevention of disease and reduction of bacterial transmission.

Designed to prevent colonization of Bordetella pertussis.

Target Audience

The primary target audience includes infants, children, adolescents, and adults at risk of pertussis infection, as well as public health organizations seeking to control the spread of the disease.